# Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

Source: https://onco.cc/trials/nct07628504/  
OnCo record `nct07628504` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sacituzumab tirumotecan and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations is a phase 3, randomised interventional study registered as NCT07628504 by Fudan University, with a registry enrolment figure of 420 participants, started 2026-05-18 and due to reach its primary completion in 2030-03-30. Interventions recorded: Sacituzumab Tirumotecan (sac-TMT); Capecitabine. Conditions listed: Adjuvant Drug Therapy. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: STARTER
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07628504
- Phase: 3
- Setting: Sacituzumab Tirumotecan (Sac-TMT) Sequential Capecitabine Versus Capecitabine as Adjuvant Regimen for Triple-Negative Breast Cancer With Early-Stage, High-Risk, Non-BRCA Mutated Status: A Phase III, Randomized, Controlled, Open-Label, Multicenter Clinical Trial
- Sponsor: Fudan University
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07628504: https://clinicaltrials.gov/study/NCT07628504

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07628504.json